drugset / Trial / NCT03837509
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2019-09-25
- Primary completion
- 2022-04-05
- Completion
- 2022-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |
| Subject | NUMIDARGISTAT | Small molecule | — | Oral |
| Background | rHuPH20 | Protein / enzyme biologic | — | Subcutaneous |